Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...

The Cambridge-based company’s latest COVID shot was approved three weeks earlier than last year, according to a statement ...

Heading into Moderna’s third-quarter earnings, investors and analysts will be watching to see how the Cambridge drugmaker ...

Q3 results confirms that the U.S. vaccine market for respiratory syncytial virus (RSV), led by Pfizer (PFE) and GSK (GSK), is ...

Stephane Bancel is stepping down as chief commercial officer of Moderna Inc., according to a person familiar with the matter.

Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...

(Reuters) -Vaccine maker Moderna's chief executive officer Stephane Bancel will vacate his role as the company's chief ...

Moderna’s third-quarter financial results look far better than analysts anticipated, but the beat seems largely to reflect ...

Moderna Inc.’s stock jumped 5% early Thursday, after the company’s third-quarter earnings showed an unexpected profit and ...

Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...

Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...

Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...